Emergency Hospitalization Due to Immune-Related Adverse Events in Cancer Patients
Author Information
Author(s): Ikeda Tatsuki, Nihei Satoru, Saito Kazuki, Asaka Junichi, Kudo Kenzo
Primary Institution: Iwate Medical University Hospital
Hypothesis
This study aimed to investigate the clinical characteristics of patients requiring emergency hospitalization due to immune-related adverse events during immune checkpoint inhibitor therapy.
Conclusion
Emergency hospitalization due to immune-related adverse events is a significant concern in immune checkpoint inhibitor therapy, highlighting the need for early monitoring and management.
Supporting Evidence
- 96 out of 1009 patients treated with immune checkpoint inhibitors required emergency hospitalization due to immune-related adverse events.
- 34.4% of patients presented with dyspnea and fatigue as chief complaints.
- 8.3% of hospitalized patients died due to immune-related adverse events.
- 33.3% of patients resumed immune checkpoint inhibitor therapy after hospitalization.
Takeaway
Some cancer treatments can cause serious side effects that make patients very sick and need to go to the hospital. It's important for doctors to watch for these problems early.
Methodology
This retrospective study evaluated patients who received immune checkpoint inhibitors at Iwate Medical University Hospital and required emergency hospitalization due to immune-related adverse events.
Potential Biases
The reliance on medical records for data may lead to inaccuracies.
Limitations
The study's retrospective design may introduce bias, and it was conducted at a single institution, limiting generalizability.
Participant Demographics
The mean age of hospitalized patients was 73 years, with 75% being male, and a high proportion undergoing treatment for lung cancer.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website